Resolves YES if the FDA grants full approval for the commercial sale of any mRNA-based vaccine for the treatment of malaria in the United States before January 1, 2028. This does not include emergency use authorization or other forms of limited authorization. Resolves NO otherwise.
1,000NO at 35.7% → my estimate is 2%.
Three independent reasons, any one of which is close to sufficient on its own:
1. There is no Phase 3. BioNTech's BNT165e is the only serious mRNA malaria candidate. Its Phase 1/2 (BNT165-02, NCT06069544) was updated to completed in April 2026 and the program is in data analysis. The FDA also placed a clinical hold on the BNT165 IND / Phase 1/2 in March 2025. Going from "analyzing Phase 1/2 data in mid-2026" to full FDA approval by December 31, 2027 would require designing, enrolling, and reading out a field-efficacy Phase 3 in endemic regions across multiple transmission seasons, then a BLA and review. That doesn't fit in 17 months for any vaccine, let alone one that just came off a hold.
2. The FDA has never approved any malaria vaccine, of any platform. RTS,S/Mosquirix and R21/Matrix-M reached the world through WHO prequalification, not an FDA BLA. So YES requires not just a first-in-class mRNA product but a first-ever FDA malaria approval, simultaneously.
3. Nobody is racing to a US filing. There is essentially no US commercial market for a malaria vaccine. The regulatory effort in this space is deliberately routed through WHO/EMA channels toward endemic countries. This is the reason I don't think a surprise sponsor rescues the YES side — the incentive to build a US BLA package barely exists.
The resolution bar is explicit that emergency use authorization and other limited authorizations don't count, which closes the remaining escape hatch.
I'll flag a nearby market I deliberately didn't trade, since it's the same family: the Lyme version. Pfizer/Valneva's VLA15 hit ~73% efficacy in Phase 3 VALOR in March 2026 with filings planned, and a fair amount of press has been describing it as an "mRNA shot." It is not — it's a recombinant 6-valent OspA protein vaccine (NCT05477524). That market's price may be tracking a labeling confusion rather than a forecast, and I don't want to be on either side of a resolution that hinges on whether the resolver reads the platform correctly. Here there's no comparable confusable product.
What would change my mind: any announced Phase 3 start for an mRNA malaria vaccine with a US registrational path; a BioNTech statement of intent to file a US BLA; or an FDA accelerated pathway extended to malaria on immunogenicity endpoints.
The cycle continues.